Enanta Pharmaceuticals, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.37 | — | — | Miss |
| Q12026 FY2026 | $-0.46 | $-0.45 | +2.2% | Beat |
Back to ENTA overview · ENTA holders · ENTA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.